Discovery on Target’s Antibody Forum offers R&D research scientists the opportunity to participate in a unique meeting format that encourages discussion and the exchange of best practices on the application of new science and technology for the discovery and development of novel biotherapeutics. The meeting will feature short presentations, panel discussions, facilitated roundtables and an audience layout that allows a sharing of ideas and experiences. Part 2 picks up at the transition from Discovery into Development, examining the screening approaches used for candidate selection, engineering problem solving and approaches for challenging molecules and new modalities.
TRANSITIONING FROM DISCOVERY TO DEVELOPMENT
Using Massive Mutational Scanning for Integrative Structure Determination, Binding Site Characterization, and Conformational Engineering of Dynamic Proteins
Erik Procko, PhD, Assistant Professor, Biochemistry, University of Illinois at Urbana-Champaign
Paratope Refinement to Mitigate Antibody Polyspecificity
Jonny Finlay, PhD, CSO, Ultrahuman, United Kingdom
Emerging Technologies to Evaluate Developability and Manufacturability
Thomas Jostock, PhD, Science and Technology Lead, Novartis, Switzerland
Case Study of AbbVie Developability Methods
Noah Pefaur, PhD, Senior Scientist, AbbVie
Creating a New Paradigm for Biotherapeutics: Attributes More Potent than Potency
Vishal Toprani, PhD, Scientist, Pharmaceutical Development, Alexion Pharmaceuticals, Inc.
ENGINEERING PROBLEM SOLVING
Engineering Human Anti-HIV Broadly Neutralizing Antibodies for Therapeutic Development
Nathan Thomsen, PhD, Senior Research Scientist, Gilead Sciences
KEYNOTE PRESENTATION: Engineering Approaches for Improving Antibody Biophysical Properties
Peter M. Tessier, PhD, Professor, Pharmaceutical Sciences and Chemical Engineering, University of Michigan
Development Stage Problem Solving
Moderator: Colby Souders, PhD, CTO, Abveris
DEVELOPMENT CHALLENGES OF NEW MODALITIES AND COMPLEX BIOLOGICS
The Application of Bispecific Antibodies in Treatment for Neurodegenerative Diseases
Zhi (Jay) Guo, PhD, Senior Scientist, Global Protein Sciences, AbbVie Bioresearch Center
Targeting Glycan-specific Epitopes
Jeff Behrens, PhD, President and CEO, Siamab Therapeutics
Please click here to return to the agenda for Antibody Forum – Part 1
Part 1 will focus on the discovery stage, offering ideas on how to accelerate and optimize these steps, emerging discovery technologies and the integration of artificial intelligence and machine learning.
* The program is subject to change without notice, due to unforeseen reason.